Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophrenia
Phase 2
Recruiting
- Conditions
- schizophrenia.???????? ?????? ? ?????F00-F98
- Registration Number
- IRCT20101130005280N31
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
2nd Generation Antipsychotic Drug use
Lack of dementia
Not taking other medicines (except anticholinergics and benzodiazepines)
No pregnancy or breastfeeding
There is no recent history of drugs (except nicotine)
schizophrenic patients during partial recovery
Exclusion Criteria
Drug side effects including: abdominal discomfort, loss of appetite resulting in weight loss, dizziness, irritability and mood swings
Occurrence of drug interactions with patient medications
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive function. Timepoint: Before intervention, end of first and second. Method of measurement: PANSS?Wisconsin? Stroop? Digit Span Questionier.
- Secondary Outcome Measures
Name Time Method